<DOC>
	<DOCNO>NCT01086293</DOCNO>
	<brief_summary>The purpose study compare incidence hospitalization acute liver failure among patient type 2 diabetes new user Saxagliptin new user oral antidiabetic drug .</brief_summary>
	<brief_title>Risk Acute Liver Failure Among Patients With Type 2 Diabetes Exposed Oral Antidiabetic Treatments</brief_title>
	<detailed_description>Prospectively design retrospective database study . This study conduct use administrative claim data electronic medical record collect part routine clinical practice</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Liver Failure , Acute</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>18 year age old Newly prescribe Saxagliptin Oral Antidiabetic Drug ( OAD ) class Dipeptidyl peptidase IV ( DPP4 ) inhibitor Enrolled respective database least 180 day prior first prescription new OAD Have least one diagnostic code type 2 diabetesrelated condition Patients identify diagnostic code acute liver failure within 180day baseline period Patients DPP4 inhibitor exposure baseline period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>